Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03667716 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | PHASE1 | COMPLETED | 121 | — | — | Sep 6, 2018 | Jan 30, 2024 | Jan 17, 2025 | 11 | United States |
To evaluate the safety profile of COM701 monotherapy and in combination with nivolumab.
| Arm | Type | Description |
|---|---|---|
| P1a Arm A (Monotherapy Dose Escalation). | EXPERIMENTAL | COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified. |
| P1a Arm B (Combination Dose Escalation). | EXPERIMENTAL | COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks. |
| P1a Arm A (Monotherapy Expansion). | EXPERIMENTAL | COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer). |
| P1b (Combination Cohort Dose Expansion). | EXPERIMENTAL | COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast, Ovarian, Endometrial and Colorectal cancer). |
| Name | Type | Description |
|---|---|---|
| COM701 | DRUG | COM701 monotherapy. |
| COM701 with Opdivo (Nivolumab). | DRUG | COM701 in combination with Opdivo (Nivolumab). |
Key Inclusion Criteria: * Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Subjects who received prior immune-stimulatory antitumor agents, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, OX-40, CD137, etc. are eligible. * Histologically or cytologically confirmed, locall...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |